fda warning letters glp-1 compounders september 2025 news compounding The Food and Drug Administration (FDA) on Tuesday Compounded" GLP-1 drugs | Health

Higher values are associated with: Impaired liver metabolism and fatty liver disease Poor glucose control and worsening insulin resistance Increased cardiovascular and stroke risk Chronic low-grade inflammation Even normal weight individuals may show elevated visceral fat on InBody analysis, revealing a hidden metabolic risk that BMI cannot detect

The impact is the same, worsening mental health issues for many

National coverage determination (NCD)

Splanchnic and pelvic spinal afferent pathways relay sensory information from the mouse colorectum into distinct brainstem circuits

Hemorrhagic pancreatitis (now specifically warned about on Ozempics label) presents unique risks for gastroparesis development due to the additional vascular damage involved

These include: Nausea and vomiting typically most pronounced during dose escalation and often improving with continued use Diarrhoea or constipation affecting bowel habit regularity Abdominal pain and discomfort ranging from mild cramping to more significant discomfort Dyspepsia and gastro-oesophageal reflux related to delayed gastric emptying Injection site reactions are classified as 'common' (affecting up to 1 in 10 people) and may include redness, itching, bruising, or localised swelling at the subcutaneous injection site